In light of the COVID-19 emergency, Radetec Diagnostics is temporarily turning its attention and resources to fight against the novel virus. Radetec’ optimised quantum dots – LFA technology has been proven effective in diagnosing various viruses that cause sexually-transmitted-infections and is therefore expected to be equally effective in diagnosing the SARS-CoV-2 virus.
Radetec is currently working closely with contract manufacturing partners around the world to bring a world-first, quantum dots-based antigen point-of-care rapid test to market as soon as possible. Our antigen-based test is expected to be materially superior to current antibody-based tests in specificity and sensitivity.
We are expecting a working prototype in July 2020.